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Induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) hold enormous
potential in many fields of cardiovascular research. Overcoming many of the limitations
of their embryonic counterparts, the application of iPSC-CMs ranges from facilitating
investigation of familial cardiac disease and pharmacological toxicity screening to
personalized medicine and autologous cardiac cell therapies. The main factor preventing
the full realization of this potential is the limited maturity of iPSC-CMs, which
display a number of substantial differences in comparison to adult cardiomyocytes.
Excitation–contraction (EC) coupling, a fundamental property of cardiomyocytes, is often
described in iPSC-CMs as being more analogous to neonatal than adult cardiomyocytes.
With Ca2+ handling linked, directly or indirectly, to almost all other properties of
cardiomyocytes, a solid understanding of this process will be crucial to fully realizing
the potential of this technology. Here, we discuss the implications of differences in
EC coupling when considering the potential applications of human iPSC-CMs in a
number of areas as well as detailing the current understanding of this fundamental
process in these cells.
Keywords: induced pluripotent stem cell-derived cardiomyocytes, excitation–contraction coupling, stem cell
maturation, disease modeling, pharmacological screening
Introduction
Induced pluripotent stem cells (iPSCs) were first described by Shinya Yamanaka and colleagues in
2006 who detailed the reprograming of adult mouse fibroblasts into a pluripotent state (Takahashi
and Yamanaka, 2006). The means to generate de novo cardiomyocytes from iPSCs was then
described in mice in 2008 (Mauritz et al., 2008; Narazaki et al., 2008) and later in human
(Zhang et al., 2009). Since then, interest in induced pluripotent stem cell-derived cardiomyocytes
(iPSC-CMs) has steadily increased. iPSC-CMs represented a step-change in stem cell research,
surmounting ethical issues surrounding consent and the use of embryonic material that has
restricted research using embryonic stem cells (ESCs), making them a much more attractive
technology to expand into wider research and industry. Furthermore, as iPSCs and their derivatives
are specific to the genetic makeup of the cell donor, whole avenues of research open up in terms of
personalized medicine and familial disease, applications that could not have been considered with
human ESC-CMs (hESC-CM).
Excitation–contraction (EC) coupling is not only one of the fundamental properties of
cardiomyocytes, turning rhythmical electrical stimulation into the production of mechanical force,
but is also central to determining many other electrophysiological and mechanical cell properties
and is a key process that becomes dysregulated in almost all cardiac diseases. Studies of EC coupling
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in human iPSC-CMs (hiPSC-CMs) have described substantial
differences between their properties and those of adult
cardiomyocytes. While understanding these differences will
be crucial to fully realizing the potential of hiPSC-CMs, research
to date is limited. Furthermore, electrophysiological study of
hiPSC-CMs is confounded by the variability of these cells in
culture. We have previously shown the markedly increased
variability in action potential morphology when hiPSC-CMs are
cultured as single cells as compared to in a monolayer. As patch
clamping studies necessitate the use of individual cells, these
findings raise questions over the usefulness of investigations
performed in this manner (Du et al., 2015).
In this mini-review we discuss the importance of EC coupling
when considering the full potential of hiPSC-CMs in a wide range
of fields, as well as detailing our current understanding of the
components of this fundamental property of cardiomyocytes.
Excitation–Contraction Coupling in
Drug Discovery and Screening
The development of new pharmacological agents is a long and
hugely expensive process, taking up to 10 years to bring a novel
agent to market with an average cost of $2.6 billion in 2014
(Mullard, 2014). In spite of the massive investment involved
in this process, FDA approvals of “new chemical entities” are
steadily declining (Paul et al., 2010). Up to 90% of compounds
that pass pre-clinical screening fail at the highly expensive clinical
trial level, with around one third showing unforeseen side-
effects (Kola and Landis, 2004). Cardiotoxicity alone accounts
for 45% of post-approval withdrawal of compounds (Stevens and
Baker, 2009). Improvements to pre-clinical screening of novel
compounds for efficacy and toxicity would provide an enormous
boon to the pharmaceutical industry, both in terms of reducing
expensive attrition rates and improving safety.
The main weakness of pre-clinical screening is the use of
in vitro and animal models that do not sufficiently reproduce
human physiology and disease. As such hiPSC-CMs are a highly
attractive option when considering replacements for current
models. There has been much discussion about the suitability
of hiPSC-CMs in this application (Khan et al., 2013; Sharma
et al., 2013; Sinnecker et al., 2014), however there is still concern
that hiPSC-CMs do not recapitulate adult human physiology
enough to be useful (Jonsson et al., 2012). Furthermore, while
industry utilizes a wide range of assays to assess drug effects,
many rely directly or indirectly on the underlying process of
EC coupling. An understanding of iPSC-CM Ca2+ handling is
therefore crucial to properly interpret these experiments and
consider their validity in the context of adult pharmacological
therapy.
Cell Therapy
A further exciting application of hiPSC-CMs is in the realm
of cell therapy, potentially providing an autologous cell source
that could be used in the treatment of a wide range of
pathologies. As has been discussed elsewhere (Chen et al.,
2009), there are a number of substantial electrophysiological
challenges that need to be overcome to successfully employ
hiPSC-CMs in cell therapy. The arrhythmogenic risks of using
electrophysiologically immature cardiomyocytes in cell therapy
has been demonstrated in detail (Zhang, 2002; Chang et al.,
2006; Lalit et al., 2014; Smit and Coronel, 2014). As such a firm
understanding of the EC coupling properties of these cells will be
important in overcoming the risks and improving the benefits of
cell therapy techniques utilizing hiPSC-CMs.
Disease Modeling
A third major area that has benefited from iPSC technology
is that of disease modeling and in particular the modeling
of inherited cardiac diseases. Since their discovery, iPSC-CM
lines for a wide range of pathologies have been developed,
such as channelopathies (Liu and Trudeau, 2015; Ma et al.,
2015); cardiomyopathies (Caspi et al., 2013; Lin et al., 2015);
as well as mutations in Ca2+ handling machinery such as
ryanodine receptors and calsequestrin (Novak et al., 2012;
Di Pasquale et al., 2013). Still, there is concern over the
ability of these cells to truly recapitulate the diseases they
model (Bellin et al., 2012; Blazeski et al., 2012; Rajamohan
et al., 2013). Indeed investigators modeling arrhythmogenic
right ventricular dysplasia using hiPSC-CMs described how
the induction of more mature metabolic properties was
essential to accurately model adult-onset cardiac disease
(Wen et al., 2015). Therefore, understanding the current
electrophysiological properties of hiPSC-CMs will be crucial for
proper interpretation of investigations into diseases modeled
in this way.
Calcium Handling in Induced Pluripotent
Stem Cell-derived Cardiomyocytes
Ca2+-induced Ca2+ release (CICR) is the key link between
electrophysiological stimulation and the production of
mechanical force as well as a feature that distinguishes
cardiomyocytes from other types of muscle cells. Cardiomyocyte
depolarization causes Ca2+ entry via voltage-sensitive L-
type Ca2+ channels, triggering the release of Ca2+ from the
sarcoplasmic reticulum (SR) via ryanodine receptors (RyR),
raising [Ca2+]i and causing contraction. Relaxation is achieved
by removing the Ca2+ from the cytosol, either by re-sequestering
it in the SR via the sarco-endoplasmic reticulum ATP-ase
(SERCA), or extruding it into the extracellular space through the
Na+-Ca2+ exchanger (NCX) or Ca2+ ATPase pump (Bers, 2002;
Figure 1).
While hiPSC-CMs show robust Ca2+ transients, they rise and
decline at a substantially slower rate (Lee et al., 2011; Hwang
et al., 2015). The rate of decline of Ca2+ transients assessed in
a number of iPSC-CM lines showed κ-values of 0.84–1.15 s−1
compared to 2.41 and 5.75 s−1 in adult rabbit and mouse
cardiomyocytes respectively (Hwang et al., 2015). Exhibiting
a strong adrenergic response (Yokoo et al., 2009; Germanguz
et al., 2011), hiPSC-CMs display a negative force-frequency
response (FFR; Germanguz et al., 2011), suggesting reduced
basal SERCA function and an inability to utilize more of their
Ca2+ stores.
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FIGURE 1 | Ultrastructural differences between adult myocytes (left) and iPSC-CMs (right) in EC coupling domains. The absence of t-tubules in iPSC-CM
is associated with the lack of regular organization of L-type Ca2+ channel (LTCC)-RyR complexes and less homogeneous distribution of RyRs. SERCA expression is
reduced with a maintained phospholamban (PLN) expression. NCX expression may be maintained but its ability to extrude Ca2+ in diastole is decreased (see main
text). Inositol-triphosphate receptor (IP3R) activity is substantially higher.
L-type Ca2+ Channels
L-type Ca2+ channels are a vital component of EC coupling
in hiPSC-CMs. We have previously shown that CaV1.2, the
α-1C subunit of L-type Ca2+ channels, demonstrates similar
expression levels to the adult human heart (Rao et al., 2013).
Application of the Ca2+ channel blocker nifedipine and removal
of [Ca2+]o both completely suppress whole cell Ca2+ transients
in these cells, demonstrating that external Ca2+ is crucial for
triggering SR Ca2+ release (Itzhaki et al., 2011). A number of
studies investigating Ca2+ current (ICa) through patch clamp
techniques have measured substantial peak current densities,
ranging from −8 pA/pF (Zhang et al., 2013b) to −17.1 ± 1.7
pA/pF at RT (Ma et al., 2011), large in comparison to H1 hESC-
CMs (Sartiani et al., 2007), although similar to mouse cardiac
myocytes (Hwang et al., 2015).
hiPSC-CMs respond to a wide range of Ca2+ channel
antagonists in a similar manner to both H7 hESC-CMs and
guinea pig myocytes (Kang et al., 2012). However, hiPSC-CMs
display unusual responses to Ca2+ channel agonists. Bay K8644
has little effect on current amplitude (Kang et al., 2012; Ji et al.,
2014), while responses to the Ca2+ channel activator FPL 64176
produced an increase in current in some cells but a reduction in
others (Kang et al., 2012). Hyperphosphorylation of channels in
heart failure is known to reduce the effect of Bay K8644 (Chen
et al., 2008) and may explain these unusual effects in hiPSC-CMs.
Understanding differences in channel pharmacology is crucial for
the use of hiPSC-CMs in drug screening platforms.
The Sarcoplasmic Reticulum
Ryanodine Receptors
High conductance Ca2+ sensitive channels in the SR membrane,
ryanodine receptors (RyRs) are the Ca2+ release mechanism
of the SR, and are closely apposed to L-type Ca2+ channels.
RYR2, the cardiac isoform of RyRs, appear diffuse throughout
the cytosol on immunostaining with reports of both intense,
punctate perinuclear (Itzhaki et al., 2011) and sub-sarcolemmal
(Zhang et al., 2013b) staining. Expression is significantly lower in
hiPSC-CMs than in H7 and HES3 hESC-CMs (Lee et al., 2011)
and the adult human heart as well as levels of its regulatory
proteins calsequestrin and triadin (Rao et al., 2013).
RyRs in hiPSC-CMs exhibit rapid, large releases of Ca2+ in
response to the agonist caffeine (Fatima et al., 2011; Itzhaki et al.,
2011; Lee et al., 2011; Kim et al., 2015; Zhang et al., 2015), and
antagonism with ryanodine reduces whole cell Ca2+ transient
amplitude. SR Ca2+ content, assessed by caffeine application, is
similar to that found in adult rabbit cells (Hwang et al., 2015).
Activation of RyRs by Ca2+ entering the cell through L-
type Ca2+ channels is crucial to the generation of mature
calcium transients and there is evidence for functional CICR
in hiPSC-CMs. hiPSC-CM transient amplitude reduced in a
dose dependent manner in response to treatment with the
selective L-type Ca2+ channel blocker nifedipine, abolishing
transients altogether at 1µM (Itzhaki et al., 2011). Further, Ca2+
transients in these cells appear to be voltage dependent, with
transient amplitude correlating positively with the size of the
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depolarization step used to activate ICa. Transients were elicited
regardless of the direction of voltage change, consistent with ICa
activation on depolarization and re-activation of ICa channels on
repolarization. This dependence on ICa rather than the direction
of voltage change distinguishes cardiac CICR from voltage-
induced Ca2+ release particular to skeletal muscle (Zhang et al.,
2013b).
The initial rise in [Ca2+]i in ICa-induced Ca2+ release has
been observed to occur at the sarcolemma before spreading
inwards, suggesting inefficient CICR, with more internal, non-
coupled RyRs being activated by the subsequent rise in [Ca2+]i
as opposed to direct activation by Ca2+ channels (Lee et al.,
2011; Zhang et al., 2013b). While a detailed EM study of iPSC-
CM ultrastructure identified some apposition of the SR with
the sarcolemma (Gherghiceanu et al., 2011), hiPSC-CMs exhibit
poor co-localization between CaV1.2 and RYR2 (Rao et al.,
2013).
Ca2+ sparks are small releases of Ca2+ from the SR generated
by the stochastic opening of small clusters of RyRs and represent
the fundamental release unit of the CICR. In keeping with the
spatial variability noted with global Ca2+ transients, Ca2+ sparks
were observed to occur repeatedly at the same sites within the
cell, with their properties differing between those occurring at
the center vs. the periphery of the cell (Zhang et al., 2013a),
suggesting an inhomogeneous clustering of RyR channels, as seen
on immunofluoresence. The majority of sparks demonstrated
multiple peaks in three-dimensional and temporal profiles,
suggesting that more than one RyR cluster may be involved in
each release event. Spark characteristics were comparable with
those of adult rat cardiomyocytes.
SERCA and Phospholamban
SERCA2a, the cardiac isoform of SERCA, is expressed in hiPSC-
CMs at significantly lower levels compared to both hESC-derived
myocytes (H7 andHES3 lines; Itzhaki et al., 2011; Lee et al., 2011)
and the adult human heart (Rao et al., 2013).
Functionally, the rate of SRCa2+ uptake is substantially slower
in hiPSC-CMs than in adult rabbit and mouse cardiomyocytes
(0.49–0.72 vs. 1.52 and 5.12 s−1 at RT; Hwang et al., 2015).
Phospholamban is a key regulator of SR function, inhibiting
SERCA activity when in its unphosphorylated form. Interestingly
PLN expression is comparable to adult human cardiomyocytes
(Rao et al., 2013); a high PLN:SERCA ratio may explain the
low basal activity (Germanguz et al., 2011), and the concurrent
ability of hiPSC-CMs to mount a strong response to adrenergic
stimulation (Yokoo et al., 2009; Germanguz et al., 2011).
Inositol-triphosphate Receptors
IP3R antagonists 2-APB and U73122 produced a significant
reduction in transient amplitude in hiPSC-CMs (Itzhaki et al.,
2011). Prominent IP3 activity is a common feature of neonatal
(Poindexter et al., 2001) and failing adult human cardiomyocytes
(Go et al., 1995; Ai et al., 2005). However, maximal application
of U73122 completely inhibited Ca2+ transients, somewhat in
conflict with the identical observation in the same study with
high concentration thapsigargin, an inhibitor of SERCA. It
has been suggested that U73122 has off target effects on SR
Ca2+ uptake (Macmillan and McCarron, 2010) but there is also
evidence to support a complex role for IP3-mediated Ca2+ release
in stem cell-derived Ca2+ handling. In mouse CMV ESC-CMs,
inhibition of IP3 production with U73122 was associated with
a decrease in spontaneous activity and Ca2+ spark frequency,
while stimulation with ET-1 had positive chronotropic effects and
increased diastolic [Ca2+]i in the presence of tetracaine (Kapur
and Banach, 2007). Whilst it is unclear exactly how IP3-mediated
Ca2+ release works together with other Ca2+ handling pathways,
future work will likely further highlight the importance of this
mechanism in iPSC-CM Ca2+ cycling.
The Sodium–Calcium Exchanger NCX
Expressed as the NCX1 isoform in the heart, NCX has a key
role in maintaining Ca2+ homeostasis, moving Ca2+ out across
the sarcolemma during systole in exchange for Na+ moving into
the cell at a ratio of 3:1 (3 Na+ ions in for each Ca2+ ion out).
Due to this stoichiometry, NCX generates a substantial inward
current (INCX) that contributes to cell depolarization, pace maker
activity and action potential duration (Blaustein and Lederer,
1999). Linking Ca2+ cycling and cell membrane potential, NCX
is one key factor in afterdepolarization-based arrhythmogenesis
and is as such of great interest as both a therapeutic target and a
source of pharmacological toxicity (Pott et al., 2011).
Expression of NCX in hiPSC-CMs is reduced compared to
two ESC-derived lines of cardiomyocytes (H7 and HES3; Lee
et al., 2011), although more recently we have shown expression
comparable to that in the adult human heart (Rao et al., 2013).
NCX currents generated on application of 2mM Ca2+showed
peak densities of 4.5± 0.5 pA/pF at 37◦C compared to an average
of <0.5 pA/pF in neonatal rat cardiomyocytes (Fine et al., 2013).
A similar effect was seen in peak INCX elicited on application of
10mM caffeine, with peak densities of ∼2.6 pA/pF in hiPSC-
CMs at 24◦C vs. ∼0.8 pA/pF in neonatal rat cardiomyocytes
(Zhang et al., 2015), correlating with reports in additional
investigations of∼2.2 pA/pF in hiPSC-CMs (Zhang et al., 2013b).
KB-R7943 reduced caffeine-induced current amplitude (Zhang
et al., 2015), demonstrating the ability of the exchanger’s forward
mode to influence resting membrane potential. To date there
has been no assessment of [Na+]i or the reversal potential
of the exchanger in hiPSC-CMs and as such the possibility
of substantial Ca2+ influx via reverse mode NCX remains
unexplored.
Regarding the relative contribution of the two main
mechanisms, SR Ca2+ uptake and NCX, to Ca2+ extrusion,
Hwang et al. have recently reported that this is similar to
adult rabbit myocytes, with approximately 60% of the Ca2+
released by caffeine removed by the SR and 40% by NCX,
which may suggest robust and adequate diastolic function
(Hwang et al., 2015). However, as previously discussed, the
rate of decline of Ca2+ transients is extremely slow in hiPSC-
CMs with both absolute values for SR Ca2+uptake and NCX-
mediated Ca2+ extrusion significantly reduced. This also stands
in contrast to the consistent observation that hiPSC-CMs display
a negative FFR, a phenomenon observed in the failing heart,
consistent with substantially reduced SR function. The similarity
Frontiers in Cell and Developmental Biology | www.frontiersin.org 4 September 2015 | Volume 3 | Article 59
Kane et al. EC Coupling of hiPSC-CMs
in relative contribution to Ca2+ extrusion may be peculiar to
the experimental conditions used (room temperature, 0.5Hz
stimulation rate) and as such need to be interpreted with caution.
In summary, hiPSC-CMs display significantly impaired diastolic
Ca2+ removal.
Spontaneous SR Ca2+ Release Events and NCX
A key feature of hiPSC-CMs is that they beat spontaneously,
making for a convenient means to confirm successful
differentiation of stem cells into cardiomyocytes. Unexpectedly,
study of this phenomenon has given us a number of insights into
the regulation of Ca2+ handling in these cells.
Optical techniques assessing spontaneous SR Ca2+ release
identified small Ca2+ wavelets propagating within the cell, the
majority of which were too small to trigger a global Ca2+ release
(Kim et al., 2015). Successive wavelets appeared to originate
repeatedly from the same sites throughout the cytosol, an
observation also made above when looking at Ca2+ sparks, which
increased in amplitude to a point where a global Ca2+ release was
triggered.
Beating rate of the cells correlated positively with the
application of isoproterenol and negatively with reduced
[Ca2+]o,as did the incidence of Ca2+ wavelets (Kim et al.,
2015). The RyR stabilizer K201 (Kim et al., 2015), inhibitors
tetracaine and ryanodine (Kim et al., 2015; Zhang et al., 2015),
the NCX inhibitor SEA0400 (Kim et al., 2015) and SERCA2a
inhibitor thapsigargin (Zhang et al., 2015) all reduced or
abolished spontaneous activity in hiPSC-CMs, confirming that
automaticity in these cells was dependent on spontaneous SR
release generating a depolarizing current via NCX. Further, a
combination of switch-clamp recording of membrane potential
and GCamP6-FKBP, a Ca2+-sensing probe targeted at RyRs,
showed that Ca2+ release events correlated with diastolic
depolarization preceding the action potential upstroke (Zhang
et al., 2015).
Mitochondrial Ca2+
The topic of mitochondrial Ca2+ in cardiomyocytes and its
consequences for Ca2+ cycling is subject to intense debate. While
it is well accepted that oscillations in mitochondrial Ca2+ occur
during cytosolic Ca2+ transients (Boyman et al., 2014), there is
conflicting evidence as to whether mitochondria play an active
or passive role in calcium cycling, be that through changes in
ATP production (Luongo et al., 2015), Ca2+ release (Zhao et al.,
2013) or buffering of cytosolic Ca2+ transients (Drago et al., 2012;
Boyman et al., 2014). A number of excellent reviews have been
written on the subject (Lukyanenko et al., 2009; Kohlhaas and
Maack, 2013).
In hiPSC-CMs, exposure to the mitochondrial uncoupler
FCCP, at low concentrations reported to enhance mitochondrial
oxidative respiration without changing membrane potential
(Brennan et al., 2006), abolished the occurrence of spontaneous
Ca2+ transients (Zhang et al., 2015). This stands in stark contrast
to the finding in mouse ventricular cardiomyocytes that identical
concentrations of FCCP enhance spontaneous SR release by
releasing Ca2+ frommitochondria (Zhao et al., 2013). The ability
of mitochondria to affect SR release is suggested to be due to
the formation of functional micro-domains between the two
structures, where small movements of Ca2+ can produce large
changes in local concentration (Lu et al., 2013). The limited
ultrastructural organization of hiPSC-CMs may mean that these
micro-domains are lost.
However, in the same study, the genetically encoded
mitochondrial Ca2+ sensing probe mitycam-E31Q revealed
that, during spontaneous depolarization, mitochondrial Ca2+
dynamics displayed regional variability, with the perinuclear
mitochondrial population releasing Ca2+ while peripheral
organelles sequestered Ca2+ (Zhang et al., 2015). While the
authors do not provide evidence as to whether this mitochondrial
Ca2+ movement precedes or is a consequence of SR Ca2+ release,
the correlation between mitochondrial Ca2+ release, cellular
micro-domains prone to spontaneous Ca2+ release events and
the perinuclear generation of whole cell Ca2+ transients suggests
mitochondrial activity plays a role in regulating Ca2+ cycling in
these cells.
Structure-function Relationships in
hiPSC-CMs
The lack of the sophisticated adult myocyte structure in hiPSC-
CMs may explain some functional observations. From studies
discussed here it is clear that SR Ca2+ release is limited in
Ca2+-induced transients, with fractional release, calculated as
1F(ICa)/1F(Caff ), averaging at ∼0.3 vs. 0.6–0.9 in adult human
cells (Bassani et al., 1995; Zhang et al., 2013b). Inhomogeneous
clustering of RyRs, the consequent loss of local control of Ca2+
release and limited association with sarcolemmal Ca2+ channels
contributes to slow and inefficient rise of [Ca2+]i. hiPSC-CMs
are devoid of t-tubules (Gherghiceanu et al., 2011), the sites of
dyad formation in the cardiomyocyte. The absence of t-tubules
in adult cells, in atrial or failing cardiomyocytes for example,
correlates with a number of properties we have discussed here
in hiPSC-CMs such as sub-sarcolemmal generation of Ca2+
transients, low fractional release and increased dependence on
sarcolemmal Ca2+ flux (Figure 1). This structural immaturity
may be a limiting step in these cells becoming more functionally
mature.
Equally so the opposite can be argued. T-tubule formation
and maintenance is an inherently energy-intensive process. Low
SERCA expression and Ca2+ extrusion rate, high PLN:SERCA
ratio and a negative force-frequency response point to decreased
SR function and regulation, associated with a greater dependence
on sarcolemmal flux to source and extrude Ca2+. As such,
greater structural co-ordination may yield limited benefits
without improvements in the underlying function of EC
coupling components, and vice-versa.
Standard culture environments place little demand on hiPSC-
CMs in terms of Ca2+ handling, and as such it could be argued
that it is more efficient to rely on sarcolemmal flux driven by
electrochemical gradients than ATP-intensive processes. We and
others have shown how using culture techniques to manipulate
myocyte structure can result in substantial changes in Ca2+
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handling properties (Kaji et al., 2003; Yin, 2004; Rao et al., 2013;
Trantidou et al., 2014).
Conclusion and Future Directions
hiPSC-CMs hold enormous promise in many fields of
cardiovascular research. While we have a reasonable
understanding of the Ca2+ handling properties of these
cells a number of questions remain, particularly with regards
to how well Ca2+ channels and RyRs are coupled and what the
dominant sources of Ca2+ are in EC coupling.
With many of the end applications of hiPSC-CMs dependent
on the ability of these cells to recapitulate adult human
cardiomyocyte properties to a satisfactory degree, differences
in channel pharmacology, mechanisms of automaticity
and structural organization between hiPSC-CMs and adult
cardiomyocytes pose challenges to fully realizing the potential
of this technology. It is important however to remember that
there is no truly definitive understanding of human cardiac
physiology. Difficulties in obtaining healthy adult tissue have
meant that the field has come to rely on failing hearts, and
in particular on rabbit physiology, as a basis of comparison.
While this by no means invalidates the comparative studies
above nor the concerns raised about hiPSC-CM function, it is
essential to consider this limitation when discussing hiPSC-CM
properties.
From a more practical perspective, the minimal variability
shown between different cells lines and different differentiation
protocols is reassuring, and gives us greater confidence
when comparing and collating the work of multiple groups.
Consideration must be given however to culture conditions, with
substantial variability in hiPSC-CM electrophysiology apparently
dependent on cell density (Du et al., 2015). Further work will
be needed to determine the general applicability of studies that
necessitate the use of single cells and to develop more suitable
alternatives.
Overall, a more solid understanding of the
electrophysiological properties and limits of hiPSC-CMs
will be extremely valuable in the interpretation of the effects of
novel drugs and making judgments on the ability of these cells to
successfully recapitulate human disease.
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